{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:24:20Z","timestamp":1793874260584,"version":"4.6.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Good Will Cause"},{"name":"MRC\/EPSRC Newcastle Pathology Node"},{"DOI":"10.13039\/501100003776","name":"Newcastle upon Tyne Hospitals NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003776","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Blood Cancer UK - Senior Bennett Fellowship #12005 North East Promenaders Against Cancer (NEPAC) The Little Princess Trust JGW Patterson Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Children with B-cell non-Hodgkin lymphoma (B-NHL) have an excellent chance of survival, however, current clinical risk stratification places as many as half of patients in a high-risk group receiving very intensive chemo-immunotherapy. <jats:italic>TP53<\/jats:italic> alterations are associated with adverse outcome in many malignancies; however, whilst common in paediatric B-NHL, their utility as a risk classifier is unknown. We evaluated the clinical significance of <jats:italic>TP53<\/jats:italic> abnormalities (mutations, deletion and\/or copy number neutral loss of heterozygosity) in a large UK paediatric B-NHL cohort and determined their impact on survival. <jats:italic>TP53<\/jats:italic> abnormalities were present in 54.7% of cases and were independently associated with a significantly inferior survival compared to those without a <jats:italic>TP53<\/jats:italic> abnormality (PFS 70.0% vs 100%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, OS 78.0% vs 100%, <jats:italic>p<\/jats:italic>\u2009=\u20090.002). Moreover, amongst patients clinically defined as high-risk (stage III with high LDH or stage IV), those without a <jats:italic>TP53<\/jats:italic> abnormality have superior survival compared to those with <jats:italic>TP53<\/jats:italic> abnormalities (PFS 100% vs 55.6%, <jats:italic>p<\/jats:italic>\u2009=\u20090.005, OS 100% vs 66.7%, <jats:italic>p<\/jats:italic>\u2009=\u20090.019). Biallelic <jats:italic>TP53<\/jats:italic> abnormalities were either maintained from the presentation or acquired at progression in all paired diagnosis\/progression Burkitt lymphoma cases. <jats:italic>TP53<\/jats:italic> abnormalities thus define clinical risk groups within paediatric B-NHL and offer a novel molecular risk stratifier, allowing more personalised treatment protocols.<\/jats:p>","DOI":"10.1038\/s41375-021-01444-6","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T07:02:48Z","timestamp":1634799768000},"page":"781-789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma"],"prefix":"10.1038","volume":"36","author":[{"given":"Alexander M.","family":"Newman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masood","family":"Zaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8045-822X","authenticated-orcid":false,"given":"Alex E.","family":"Blain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Erhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Barnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Crossland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Enshaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"De Zordi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Taj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina M.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Televantou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8439-4507","authenticated-orcid":false,"given":"Suzanne D.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2671-9972","authenticated-orcid":false,"given":"G. A. Amos","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Bomken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris M.","family":"Bacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2198-8949","authenticated-orcid":false,"given":"Vikki","family":"Rand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"key":"1444_CR1","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","volume":"109","author":"C Patte","year":"2007","unstructured":"Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, et al. Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773\u201380.","journal-title":"Blood"},{"key":"1444_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/leu.2008.312","volume":"23","author":"HA Poirel","year":"2009","unstructured":"Poirel HA, Cairo MS, Heerema NA, Swansbury J, Auperin A, Launay E, et al. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin\u2019s lymphoma: results of the FAB\/LMB 96 international study. Leukemia. 2009;23:323\u201331.","journal-title":"Leukemia"},{"key":"1444_CR3","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.2014.59.5827","volume":"33","author":"V Minard-Colin","year":"2015","unstructured":"Minard-Colin V, Brugieres L, Reiter A, Cairo MS, Gross TG, Woessmann W, et al. Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead. J Clin Oncol: Off J Am Soc Clin Oncol. 2015;33:2963\u201374.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"1444_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1200\/JCO.2010.33.3369","volume":"30","author":"MS Cairo","year":"2012","unstructured":"Cairo MS, Sposto R, Gerrard M, Auperin A, Goldman SC, Harrison L, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (>\/= 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin\u2019s lymphoma: results of the FAB LMB 96 study. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30:387\u201393.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"1444_CR5","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","volume":"382","author":"V Minard-Colin","year":"2020","unstructured":"Minard-Colin V, Auperin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, et al. Rituximab for high-risk, mature b-cell non-hodgkin\u2019s lymphoma in children. N Engl J Med. 2020;382:2207\u201319.","journal-title":"N Engl J Med"},{"key":"1444_CR6","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1200\/JCO.19.00525","volume":"37","author":"MJ Ehrhardt","year":"2019","unstructured":"Ehrhardt MJ, Chen Y, Sandlund JT, Bluhm EC, Hayashi RJ, Becktell K, et al. Late health outcomes after contemporary lymphome Malin de Burkitt therapy for mature B-Cell Non-Hodgkin lymphoma: a report from the childhood cancer survivor study. J Clin Oncol: Off J Am Soc Clin Oncol. 2019;37:2556\u201370.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"1444_CR7","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41375-020-0841-x","volume":"35","author":"A Attarbaschi","year":"2020","unstructured":"Attarbaschi A, Carraro E, Ronceray L, Andres M, Barzilai-Birenboim S, Bomken S, et al. Second malignant neoplasms after treatment of non-Hodgkin\u2019s lymphoma-a retrospective multinational study of 189 children and adolescents. Leukemia. 2020;35:534\u201349.","journal-title":"Leukemia"},{"key":"1444_CR8","doi-asserted-by":"crossref","unstructured":"Srinivasan S, Roy Moulik N, Kc A, Narula G, Sankaran H, Prasad M, et al. Increased toxicities in children with Burkitt lymphoma treated with rituximab: experience from a tertiary cancer center in India. Pediatr Blood Cancer. 2020;67(11):e28682.","DOI":"10.1002\/pbc.28682"},{"key":"1444_CR9","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","volume":"109","author":"MS Cairo","year":"2007","unstructured":"Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109:2736\u201343.","journal-title":"Blood"},{"key":"1444_CR10","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.3109\/10428194.2012.677534","volume":"53","author":"P Anoop","year":"2012","unstructured":"Anoop P, Sankpal S, Stiller C, Tewari S, Lancaster DL, Khabra K, et al. Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. Leuk lymphoma. 2012;53:1882\u20138.","journal-title":"Leuk lymphoma"},{"key":"1444_CR11","doi-asserted-by":"publisher","first-page":"810","DOI":"10.3324\/haematol.2014.121434","volume":"100","author":"A Jourdain","year":"2015","unstructured":"Jourdain A, Auperin A, Minard-Colin V, Aladjidi N, Zsiros J, Coze C, et al. Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective \u201cLymphomes Malins B\u201d protocols. A Societe Francaise des Cancers de l\u2019Enfant study. Haematologica. 2015;100:810\u20137.","journal-title":"Haematologica"},{"key":"1444_CR12","doi-asserted-by":"publisher","first-page":"e27873","DOI":"10.1002\/pbc.27873","volume":"66","author":"C Rigaud","year":"2019","unstructured":"Rigaud C, Auperin A, Jourdain A, Haouy S, Couec ML, Aladjidi N, et al. Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study. Pediatr Blood Cancer. 2019;66:e27873.","journal-title":"Pediatr Blood Cancer"},{"key":"1444_CR13","first-page":"1124","volume":"135","author":"W Woessmann","year":"2020","unstructured":"Woessmann W, Zimmermann M, Meinhardt A, Muller S, Hauch H, Knorr F, et al. Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy. Blood. 2020;135:1124\u201332.","journal-title":"Blood"},{"key":"1444_CR14","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1038\/s41375-020-0749-5","volume":"34","author":"GAA Burke","year":"2020","unstructured":"Burke GAA, Beishuizen A, Bhojwani D, Burkhardt B, Minard-Colin V, Norris RE, et al. Ibrutinib plus CIT for R\/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy. Leukemia. 2020;34:2271\u20135.","journal-title":"Leukemia"},{"key":"1444_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejca.2019.01.013","volume":"110","author":"ADJ Pearson","year":"2019","unstructured":"Pearson ADJ, Scobie N, Norga K, Ligas F, Chiodin D, Burke A, et al. ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. Eur J Cancer. 2019;110:74\u201385.","journal-title":"Eur J Cancer"},{"key":"1444_CR16","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/ng.2468","volume":"44","author":"C Love","year":"2012","unstructured":"Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012;44:1321\u20135.","journal-title":"Nat Genet"},{"key":"1444_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nature11378","volume":"490","author":"R Schmitz","year":"2012","unstructured":"Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490:116\u201320.","journal-title":"Nature"},{"key":"1444_CR18","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1182\/blood.2019001880","volume":"134","author":"RI Panea","year":"2019","unstructured":"Panea RI, Love CL, Shingleton JR, Reddy A, Bailey JA, Moormann AM, et al. The whole genome landscape of Burkitt lymphoma subtypes. Blood. 2019;134:1598\u2013607.","journal-title":"Blood"},{"key":"1444_CR19","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1182\/blood-2018-09-871418","volume":"133","author":"BM Grande","year":"2019","unstructured":"Grande BM, Gerhard DS, Jiang A, Griner NB, Abramson JS, Alexander TB, et al. Genome-wide discovery of somatic coding and non-coding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood. 2019;133:1313\u201324.","journal-title":"Blood"},{"key":"1444_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08578-3","volume":"10","author":"C Lopez","year":"2019","unstructured":"Lopez C, Kleinheinz K, Aukema SM, Rohde M, Bernhart SH, Hubschmann D, et al. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. Nat Commun. 2019;10:1459.","journal-title":"Nat Commun"},{"key":"1444_CR21","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679\u201390.","journal-title":"Nat Med"},{"key":"1444_CR22","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-Cell lymphoma. N Engl J Med. 2018;378:1396\u2013407.","journal-title":"N Engl J Med"},{"key":"1444_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","volume":"171","author":"A Reddy","year":"2017","unstructured":"Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171:481\u201394.","journal-title":"Cell"},{"key":"1444_CR24","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood.2019003535","volume":"135","author":"SE Lacy","year":"2020","unstructured":"Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood. 2020;135:1759\u201371.","journal-title":"Blood"},{"key":"1444_CR25","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1073\/pnas.1121343109","volume":"109","author":"JG Lohr","year":"2012","unstructured":"Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA. 2012;109:3879\u201384.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1444_CR26","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1073\/pnas.1205299110","volume":"110","author":"J Zhang","year":"2013","unstructured":"Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2013;110:1398\u2013403.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1444_CR27","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1182\/blood-2013-02-483727","volume":"122","author":"RD Morin","year":"2013","unstructured":"Morin RD, Mungall K, Pleasance E, Mungall AJ, Goya R, Huff RD, et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood. 2013;122:1256\u201365.","journal-title":"Blood"},{"key":"1444_CR28","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/ng.892","volume":"43","author":"L Pasqualucci","year":"2011","unstructured":"Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43:830\u20137.","journal-title":"Nat Genet"},{"key":"1444_CR29","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1101\/gad.13.20.2658","volume":"13","author":"CM Eischen","year":"1999","unstructured":"Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13:2658\u201369.","journal-title":"Genes Dev"},{"key":"1444_CR30","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1038\/onc.2011.191","volume":"30","author":"MA Rowh","year":"2011","unstructured":"Rowh MA, DeMicco A, Horowitz JE, Yin B, Yang-Iott KS, Fusello AM, et al. Tp53 deletion in B lineage cells predisposes mice to lymphomas with oncogenic translocations. Oncogene. 2011;30:4757\u201364.","journal-title":"Oncogene"},{"key":"1444_CR31","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1182\/blood-2011-11-366062","volume":"119","author":"ZY Xu-Monette","year":"2012","unstructured":"Xu-Monette ZY, Medeiros LJ, Li Y, Orlowski RZ, Andreeff M, Bueso-Ramos CE, et al. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood. 2012;119:3668\u201383.","journal-title":"Blood"},{"key":"1444_CR32","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1101\/gad.314286.118","volume":"32","author":"BJ Aubrey","year":"2018","unstructured":"Aubrey BJ, Janic A, Chen Y, Chang C, Lieschke EC, Diepstraten ST, et al. Mutant TRP53 exerts a target gene-selective dominant-negative effect to drive tumor development. Genes Dev. 2018;32:1420\u20139.","journal-title":"Genes Dev"},{"key":"1444_CR33","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","volume":"170","author":"ER Kastenhuber","year":"2017","unstructured":"Kastenhuber ER, Lowe SW. Putting p53 in Context. Cell. 2017;170:1062\u201378.","journal-title":"Cell"},{"key":"1444_CR34","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","volume":"120","author":"ZY Xu-Monette","year":"2012","unstructured":"Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012;120:3986\u201396.","journal-title":"Blood"},{"key":"1444_CR35","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/ijc.30838","volume":"141","author":"T Zenz","year":"2017","unstructured":"Zenz T, Kreuz M, Fuge M, Klapper W, Horn H, Staiger AM, et al. TP53 mutation and survival in aggressive B cell lymphoma. Int J Cancer. 2017;141:1381\u20138.","journal-title":"Int J Cancer"},{"key":"1444_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0089-0","volume":"8","author":"AM Intlekofer","year":"2018","unstructured":"Intlekofer AM, Joffe E, Batlevi CL, Hilden P, He J, Seshan VE, et al. Integrated DNA\/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood Cancer J. 2018;8:60.","journal-title":"Blood Cancer J"},{"key":"1444_CR37","doi-asserted-by":"publisher","first-page":"e0174809","DOI":"10.1371\/journal.pone.0174809","volume":"12","author":"P Xu","year":"2017","unstructured":"Xu P, Liu X, Ouyang J, Chen B. TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis. PLoS One. 2017;12:e0174809.","journal-title":"PLoS One"},{"key":"1444_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/cjp2.10","volume":"1","author":"A Clipson","year":"2015","unstructured":"Clipson A, Barrans S, Zeng N, Crouch S, Grigoropoulos NF, Liu H, et al. The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit. J Pathol Clin Res. 2015;1:125\u201333.","journal-title":"J Pathol Clin Res"},{"key":"1444_CR39","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3324\/haematol.2018.187583","volume":"103","author":"E Campo","year":"2018","unstructured":"Campo E, Cymbalista F, Ghia P, Jager U, Pospisilova S, Rosenquist R, et al. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. Haematologica. 2018;103:1956\u201368.","journal-title":"Haematologica"},{"key":"1444_CR40","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th Edition edn. International Agency for Research on Cancer (IARC), 2017."},{"key":"1444_CR41","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood-2004-03-0973","volume":"105","author":"W Woessmann","year":"2005","unstructured":"Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105:948\u201358.","journal-title":"Blood"},{"key":"1444_CR42","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/humu.23035","volume":"37","author":"L Bouaoun","year":"2016","unstructured":"Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J, et al. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. Hum Mutat. 2016;37:865\u201376.","journal-title":"Hum Mutat"},{"key":"1444_CR43","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/humu.22552","volume":"35","author":"B Leroy","year":"2014","unstructured":"Leroy B, Anderson M, Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Hum Mutat. 2014;35:672\u201388.","journal-title":"Hum Mutat"},{"key":"1444_CR44","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","volume":"28","author":"LA Donehower","year":"2019","unstructured":"Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, et al. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. Cell Rep. 2019;28:1370\u201384.","journal-title":"Cell Rep"},{"key":"1444_CR45","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ccr.2012.07.014","volume":"22","author":"S Monti","year":"2012","unstructured":"Monti S, Chapuy B, Takeyama K, Rodig SJ, Hao Y, Yeda KT, et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 2012;22:359\u201372.","journal-title":"Cancer Cell"},{"key":"1444_CR46","doi-asserted-by":"publisher","first-page":"a026096","DOI":"10.1101\/cshperspect.a026096","volume":"6","author":"CM Eischen","year":"2016","unstructured":"Eischen CM. Genome Stability Requires p53. Cold Spring Harb Perspect Med. 2016;6:a026096.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1444_CR47","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1182\/blood-2013-06-507996","volume":"123","author":"I Salaverria","year":"2014","unstructured":"Salaverria I, Martin-Guerrero I, Wagener R, Kreuz M, Kohler CW, Richter J, et al. A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood. 2014;123:1187\u201398.","journal-title":"Blood"},{"key":"1444_CR48","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/bjh.13501","volume":"170","author":"SM Aukema","year":"2015","unstructured":"Aukema SM, Theil L, Rohde M, Bauer B, Bradtke J, Burkhardt B, et al. Sequential karyotyping in Burkitt lymphoma reveals a linear clonal evolution with increase in karyotype complexity and a high frequency of recurrent secondary aberrations. Br J Haematol. 2015;170:814\u201325.","journal-title":"Br J Haematol"},{"key":"1444_CR49","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41375-020-0862-5","volume":"35","author":"K Reutter","year":"2020","unstructured":"Reutter K, Sandmann S, Rohde J, Muller S, Woste M, Khanam T, et al. Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma. Leukemia. 2020;35:639\u201343.","journal-title":"Leukemia"},{"key":"1444_CR50","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1365-2141.2011.08883.x","volume":"155","author":"JD Schiffman","year":"2011","unstructured":"Schiffman JD, Lorimer PD, Rodic V, Jahromi MS, Downie JM, Bayerl MG, et al. Genome wide copy number analysis of paediatric Burkitt lymphoma using formalin-fixed tissues reveals a subset with gain of chromosome 13q and corresponding miRNA over expression. Br J Haematol. 2011;155:477\u201386.","journal-title":"Br J Haematol"},{"key":"1444_CR51","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.3324\/haematol.2010.026831","volume":"95","author":"R Scholtysik","year":"2010","unstructured":"Scholtysik R, Kreuz M, Klapper W, Burkhardt B, Feller AC, Hummel M, et al. Detection of genomic aberrations in molecularly defined Burkitt\u2019s lymphoma by array-based, high resolution, single nucleotide polymorphism analysis. Haematologica. 2010;95:2047\u201355.","journal-title":"Haematologica"},{"key":"1444_CR52","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/bjh.13925","volume":"173","author":"V Havelange","year":"2016","unstructured":"Havelange V, Pepermans X, Ameye G, Theate I, Callet-Bauchu E, Barin C, et al. Genetic differences between paediatric and adult Burkitt lymphomas. Br J Haematol. 2016;173:137\u201344.","journal-title":"Br J Haematol"},{"key":"1444_CR53","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/ijc.29072","volume":"136","author":"R Scholtysik","year":"2015","unstructured":"Scholtysik R, Kreuz M, Hummel M, Rosolowski M, Szczepanowski M, Klapper W, et al. Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis. Int J Cancer. 2015;136:1033\u201342.","journal-title":"Int J Cancer"},{"key":"1444_CR54","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.3324\/haematol.2017.168872","volume":"102","author":"S Thanendrarajan","year":"2017","unstructured":"Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, et al. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017;102:e364\u2013e367.","journal-title":"Haematologica"},{"key":"1444_CR55","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","volume":"33","author":"BA Walker","year":"2019","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33:159\u201370.","journal-title":"Leukemia"},{"key":"1444_CR56","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549\u201356.","journal-title":"Nat Med"},{"key":"1444_CR57","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1126\/science.aax3649","volume":"365","author":"S Boettcher","year":"2019","unstructured":"Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019;365:599\u2013604.","journal-title":"Science"},{"key":"1444_CR58","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1080\/10428194.2017.1413186","volume":"59","author":"CM Wever","year":"2018","unstructured":"Wever CM, Geoffrion D, Grande BM, Yu S, Alcaide M, Lemaire M, et al. The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples. Leuk lymphoma. 2018;59:2159\u201374.","journal-title":"Leuk lymphoma"},{"key":"1444_CR59","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/leu.2017.251","volume":"32","author":"K Karube","year":"2018","unstructured":"Karube K, Enjuanes A, Dlouhy I, Jares P, Martin-Garcia D, Nadeu F, et al. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia. 2018;32:675\u201384.","journal-title":"Leukemia"},{"key":"1444_CR60","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cell.2011.12.013","volume":"148","author":"T Rausch","year":"2012","unstructured":"Rausch T, Jones DT, Zapatka M, Stutz AM, Zichner T, Weischenfeldt J, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell. 2012;148:59\u201371.","journal-title":"Cell"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01444-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01444-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01444-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T21:04:07Z","timestamp":1675803847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01444-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1444"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01444-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,21]]},"assertion":[{"value":"2 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}